Skip to main content

Scorpion Therapeutics to Present Preclinical Proof-of-Concept Data for Highly Selective, Next-Generation Exon 20 Mutant EGFR Inhibitor at 34th EORTC-NCI-AACR Symposium

Investigational new drug (“IND”) application submission for STX-721 expected in 2023

BOSTON, Mass. – October 12, 2022 – Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering oncology company redefining the frontier of precision medicine, today announced that it will present preclinical proof-of-concept data for STX-721 in a poster session at the European Organisation for Research and Treatment of Cancer, the National Cancer Institute, and the American Association for Cancer Research (“EORTC-NCI-AACR”) Symposium 2022 in Barcelona, Spain, taking place October 26 – 28, 2022.

STX-721 (formerly ST-5924) is Scorpion’s next-generation, orally delivered, small molecule designed with potential best-in-class selectivity for exon 20 insertion mutations in epidermal growth factor receptors (“EGFR”), a well-known, clinically validated oncogenic driver in non-small cell lung cancer (“NSCLC”). STX-721 is progressing through preclinical studies and Scorpion expects to submit an IND application to the U.S. Food and Drug Administration in 2023.

“We are excited to share foundational proof-of-concept data for STX-721, our next-generation EGFR inhibitor, which supports its potentially best-in-class product profile,” said Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion Therapeutics. “The Scorpion team developed this small molecule with the goal of delivering superior selectivity, as well as improved safety, tolerability and efficacy compared to currently marketed EGFR Exon 20 therapies and other drug candidates in development. We believe STX-721 could meaningfully improve the treatment of people living with EGFR exon 20-mutant NSCLC and look forward to advancing into clinical studies next year.”

Details of the poster presentation are as follows:

Presentation Title: Identification of ST-5924, an EGFR Exon 20 Mutant Inhibitor with Superior Selectivity and a Potential Best-In-Class Profile
Session Title: New Drugs
Abstract Number: 84
Poster Board Number: PB074
Date & Time: Wednesday, Oct 26, 2022 at 12:00 – 20:00 CEST (6:00 a.m. – 2:00 p.m. ET)
Location: Centre de Convencions Internacional Barcelona (CCIB), Exhibition Hall

The abstract is now available online on the EORTC-NCI-AACR conference website at

About Scorpion Therapeutics

Scorpion is a pioneering oncology company redefining the frontier of precision medicine to deliver optimized and transformational therapies for larger populations of patients with cancer, a strategy Scorpion refers to as Precision Oncology 2.0. Scorpion has built a proprietary and fully integrated platform of the most advanced technologies across cancer biology, medicinal chemistry, and data sciences, with the goal of consistently and rapidly creating exquisitely selective small molecule compounds against an unprecedented spectrum of targets. Scorpion aims to leverage its platform to advance a broad pipeline of wholly owned, optimized compounds across three target categories: best-in-class molecules targeting validated oncogene targets; first-in-class molecules for previously undruggable targets; and first-in-class molecules for novel cancer targets. For more information, visit

Media Contact:
Ravi Moorthy
Scorpion Therapeutics

Investor Contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.